Hereditary condition

Herceptin Hylecta (also known as trastuzumab and hyaluronidase-oysk) is a biologic drug used in the treatment of HER2-positive breast cancer. It is a combination of trastuzumab, a monoclonal antibody that targets the HER2 protein, and hyaluronidase, an enzyme that helps the body absorb the drug.

Mechanism of Action[edit | edit source]

Herceptin Hylecta works by targeting the HER2 protein, which is overexpressed in certain types of breast cancer. The trastuzumab component of the drug binds to the HER2 protein, blocking it from receiving growth signals. This helps to slow or stop the growth of the cancer cells. The hyaluronidase component of the drug helps the body absorb the trastuzumab, allowing it to reach the cancer cells more effectively.

Uses[edit | edit source]

Herceptin Hylecta is used to treat HER2-positive breast cancer, a type of cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. It is used in both the early and metastatic stages of the disease.

Side Effects[edit | edit source]

Like all medications, Herceptin Hylecta can cause side effects. Common side effects include fatigue, joint pain, diarrhea, injection site reactions, upper respiratory tract infection, rash, muscle pain, nausea, headache, edema, flushing, fever, and chills. Serious side effects can include heart problems, lung problems, serious infections, and severe allergic reactions.

Administration[edit | edit source]

Herceptin Hylecta is administered by subcutaneous injection, typically once every three weeks. The injection is given in the thigh and can be administered at home by a healthcare provider.